OXADIAZOLIDINONE COMPOUND Russian patent published in 2012 - IPC C07D271/06 C07D413/12 A61K31/4245 A61K31/4439 A61P3/08 A61P3/10 A61P43/00 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to oxadiazolidinone compounds presented by following formula (I), or to their pharmaceutically acceptable salts, (symbols in the presented formula represent the following values, R¹: -H, R⁰: lower alkyl, R^z: the same or different from each other, and each represents -H or lower alkyl, L: *-CH₂-O- or *-CH₂-NH-, where the symbol * in L represents binding with the ring A and a substitution position in the group L in the ring B represents the 4-position, the ring A: benzole, the ring B: benzole or pyridine, R²; the same or different respectively, and each represents -halogen or -R⁰, n: 0 or 1, R³: phenyl which can be substituted by a group selected from the group G³, The group G³: halogen, -R⁰, halogen-lower alkyl, -OR^z, -CON(R^z)₂, -CON(R^z)-heteroring group, -O-S(O)₂-R⁰, -O-lower alkylene-OR^z, -O-lower alkylene-O-COR², -O-lower alkylene-N(R^Z)₂, -O-lower alkylene-N(R^z)CO-R^z, -O-lower alkylene-CO₂R^z, -O-lower alkylene-CON(R^z)₂, -O-lower alkylene-CON(R^z)-(lower alkyl substituted by the group-OR^z), -O-lower alkylene-SR⁰, -O-lower alkylene-cycloalkyl, -O-lower alkylene-CON(R^z)-cycloalkyl, -O-lower alkylene-heteroring group and -O-lower alkylene-CON(R^z)-heteroring group, where lower alkylene in the group G³ can be substituted by halogen or -OR^z, and cycloalkyl and the heteroring group in the group G³ can be substituted by the group selected by the group G¹, The group G¹: halogen, cyano, -R⁰, -OR^z, -N(R^Z)₂, -S-R⁰, -SO₂-R⁰, -SO₂N(R^z)₂, -CO-R², -CON(R^z)₂, -CON(R^z)-lower alkylene-OR², -N(R^z)CO-R^z, oxo, -(lower alkylene which can be substituted by the group -OR^z)-aryl, heteroring group and lower alkylene-heteroring group where aryl and the heteroring group in the group G¹ can be substituted by the group selected from the following group G², the group G²: halogen, cyano where the heteroring group means a group containing a ring selected from i) a monocyclic 5-7-members, saturated or unsaturated heteroring containing 1 to 3 heteroatoms selected from O, S and N, ii) a bicyclic heteroring in which the heterorings selected in i) mentioned above are ring-condensed where the condensed rings can be the same or different, and iii) the bicyclic heteroring in which the heteroring selected in i) mentioned above is condensed with a benzoic ring or 5-7-members cycloalkane, R⁴: -H. The invention refers to a pharmaceutical composition, to application of the compounds under cl.1, as well as to a method for preventing and/or treating diabetes.

EFFECT: making new biologically active compounds representing GPR40 agonist, an agent stimulating insulin secretion and/or an agent for preventing and/or treating diabetes.

9 cl, 27 ex, 138 tbl